Cancer
Conditions
Interventions
Gastric cancer:N/A
Cervical Cancer:N/A
Bladder cancer:N/A
Sponsors
Peking University Cancer Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria for gastric cancer: 1. Age: 18 to 75 years old 2. Patients diagnosed with stage II-III gastric cancer through histopathological examination 3. The disease status score of the Eastern Cooperative Oncology Group (ECOG) was 0-1 4. There is no pleural effusion. Ascites in the pelvic cavity exceeds the pelvic area. Abdominal and pelvic CT scans confirm no metastasis to the peritoneum, liver or other distant organs 5. Voluntarily participate, sign the informed consent form, and demonstrate a good willingness to cooperate with the follow-up Inclusion criteria for cervical cancer: 1. Age >=18 years old 2. Cervical cancer was diagnosed through histopathological examination 3. Has not received anti-tumor treatments such as surgery, radiotherapy or chemotherapy in the past 4. There have been no other types of tumor-related diseases in the past 5. The relevant clinical medical record materials are complete 6. Voluntary participation and signing of informed consent form Inclusion criteria for bladder cancer: 1. Age >=18 years old 2. Newly diagnosed patients with non-muscle-invasive bladder cancer through histopathological examination 3. Patients who develop hematuria or positive exfoliated cells in urine after receiving anti-tumor treatment, or whose recurrence is indicated by imaging 4. The relevant clinical medical record materials are complete 5. Voluntarily participate, sign the informed consent form, and demonstrate a good willingness to cooperate with the follow-up
Exclusion criteria
Exclusion criteria: Exclusion criteria for gastric cancer: Positive resection margins were found in the postoperative pathology 2. Patients who have suffered from or are currently suffering from other malignant tumors 3. The patient requires emergency surgery due to complications caused by gastric cancer 4. Patients who have not signed the informed consent for clinical testing or have refused to participate in clinical research 5. The researcher determined that the patient's clinical specimen was not suitable for participation in this study 6. Improper collection or preservation of specimens makes genetic testing impossible 7. Missing clinical data or non-standard records 8. Patients who do not receive follow-up Exclusion criteria for cervical cancer: Patients who have suffered from or are currently suffering from other malignant tumors 2. Patients with missing clinical data or non-standard records, and incomplete medical record information 3. Patients who are unable to provide samples for testing due to various reasons 4. Patients who have not signed the informed consent for clinical testing or have refused to participate in clinical research 5. The researcher determined that the patient's clinical specimen was not suitable for participation in this study 6. Improper collection or preservation of specimens makes genetic testing impossible Exclusion criteria for bladder cancer: Patients who have suffered from or are currently suffering from other malignant tumors 2. Patients with missing clinical data or non-standard records, and incomplete medical record information 3. Patients who are unable to provide samples for testing due to various reasons 4. Patients who have not signed the informed consent for clinical testing or have refused to participate in clinical research 5. The researcher determined that the patient's clinical specimen was not suitable for participation in this study 6. Improper collection or preservation of specimens makes genetic testing impossible 7. Patients who do not receive follow-up
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Recurrence free survival;MRD detection; | — |
Countries
China
Contacts
Public ContactJia Shuqin
Peking University Cancer Hospital & Institute
Outcome results
None listed